Stockreport

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF Data demonstrate that extracellular ASC specks, independent of IL-1ß, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which is characterized by deposit [Read more]